Redeye comments on Physitrack’s announcement regarding the divestment of its German wellness subsidiary, Wellnow. The transaction will result in a revenue reduction of approximately EUR1.7m for the Group but is expected to generate annual net cost savings of at least EUR0.15m. We view this divestment positively, as the management buyout (MBO) aligns with Physitrack’s strategic transition towards high-margin, recurring-revenue business models, thereby enhancing overall group margins.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/